StageZero Life Sciences Ltd. Share Price

Equities

SZLS

CA8525403017

Biotechnology & Medical Research

Market Closed - Toronto S.E. 08:30:00 16/04/2024 pm IST 5-day change 1st Jan Change
0.04 CAD 0.00% Intraday chart for StageZero Life Sciences Ltd. 0.00% -11.11%

Financials

Sales 2021 5.07M 6.93M 423M Sales 2022 3.8M 5.19M 316M Capitalization 4.49M 6.14M 375M
Net income 2021 -7M -9.57M -584M Net income 2022 -11M -15.04M -917M EV / Sales 2021 3.99 x
Net cash position 2021 368K 504K 30.72M Net Debt 2022 1.78M 2.44M 149M EV / Sales 2022 1.65 x
P/E ratio 2021
-2.2 x
P/E ratio 2022
-0.39 x
Employees 40
Yield 2021 *
-
Yield 2022
-
Free-Float 79.63%
More Fundamentals * Assessed data
Dynamic Chart
Current month-20.00%
1 month-27.27%
3 months-11.11%
6 months-20.00%
Current year-11.11%
More quotes
1 month
0.04
Extreme 0.04
0.06
Current year
0.04
Extreme 0.04
0.06
1 year
0.04
Extreme 0.035
0.08
3 years
0.04
Extreme 0.035
0.79
5 years
0.04
Extreme 0.035
1.65
10 years
0.00
Extreme 0
15.52
More quotes
Managers TitleAgeSince
Chief Executive Officer - 01/02/01
Investor Relations Contact - -
Members of the board TitleAgeSince
Founder 71 01/98/01
Director/Board Member 90 01/00/01
Chief Executive Officer - 01/02/01
More insiders
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.
More about the company